Virtuozzo Named Cloud Enabler of the Year at the Storage Awards XIX
13.6.2022 18:47:00 EEST | Business Wire | Press release
Virtuozzo, the alternative cloud platform leader, today announced it was named Cloud Enabler of the Year during the 19th annual Storage Awards hosted by Storage Magazine. Filling a void in the cloud enablement market, Virtuozzo delivers a robust cloud platform for service providers that is easy to use and manage. The honor recognizes the company’s commitment to enabling these providers to rapidly launch an extensive portfolio of scalable cloud services that are viable, cost-effective alternatives to hyperscaler solutions.
The Storage Awards, also known as the Storries, recognize the finest products, companies, and people revolutionizing storage technology. Winners are chosen by Storage Magazine readers, making it one of the few programs driven by an independent selection committee comprised of users and IT decision makers. Virtuozzo was one of twelve nominees in the Cloud Enabler of the Year category and was a contender in five other categories—including Cloud Company of the Year for which it was named runner-up.
“Winning the Storage Award is an achievement we deeply appreciate,” said Alex Fine, CEO, Virtuozzo. “We understand that the decision was made by IT industry members who work with and understand what cloud solutions need to be, what they should enable to be truly beneficial to end users. We are committed to helping service providers generate revenue through competitive, easy-to-use solutions that offer growth and opportunity. As its adoption continues, we believe that Virtuozzo delivers on that promise.”
Fast, Easy, Lower-Cost Cloud
Virtuozzo delivers everything ranging from Infrastructure-as-a-Service (IaaS) to platform-as-a-Service (PaaS) in a single cloud platform. It is purpose-built for hosting, cloud and managed service providers (HSPs, CSPs, and MSPs) complete with features and functions designed to help them easily implement and manage extensive, scalable cloud product portfolios. The simplicity of Virtuozzo frees service providers to focus on differentiating products as well as hands-on customer support—enabling them to quickly reach profitability while helping their users maximize their cloud investments.
Further, Virtuozzo offers its partners a full suite of professional services that help them go to market quickly and efficiently. These include Product Installation, Managed Cloud, Training, and Consulting among others—establishing a true, mutually beneficial collaboration.
About Virtuozzo
Virtuozzo (www.virtuozzo.com) provides the leading alternative cloud platform for service providers, enabling them to sell cloud services that are more accessible, more affordable and easier to use than hyperscaler solutions. The company’s legacy includes developing the first commercially available container technology and being a major contributor to numerous virtualization and open-source projects for more than 20 years. Today, Virtuozzo cloud solutions are used by more than 700 Cloud Service Providers, Managed Service Providers and Hosting Providers in 80 countries. Virtuozzo is based in Schaffhausen, Switzerland, and has more than 320 employees across the U.S., UK, Europe, and Asia-Pacific.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005614/en/
Contact information
Heather Ailara
211 Communications
+1.973.567.6040
heather@211comms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 08:03:00 EEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
